161 results on '"Marquet, Pierre"'
Search Results
2. In Silico Pharmacokinetics Evaluation of Forgiveness for Doravirine and Rilpivirine
3. In Silico Pharmacokinetics Evaluation of Forgiveness for Doravirine and Rilpivirine
4. Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant Recipients
5. Longitudinal Exposure to Tacrolimus and New-Onset Diabetes Mellitus in Renal Transplant Patients
6. Relationships Between Tacrolimus Exposure and Adverse Events in Renal Transplant Patients: The ExpoTac Study.
7. Getting Tacrolimus Dosing Right.
8. Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
9. Population Pharmacokinetics and Limited Sampling Strategy of Mycophenolate Mofetil for Indian Patients With Lupus Nephritis
10. A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis
11. Tacrolimus Bayesian dose adjustment in pediatric renal transplant recipients
12. Phenotyping of Uracil and 5-Fluorouracil Metabolism Using LC-MS/MS for Prevention of Toxicity and Dose Adjustment of Fluoropyrimidines
13. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
14. Pharmacodynamic Monitoring of mTOR Inhibitors
15. Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives—An Interview in Honor of Professor Charles Pippenger
16. Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant Recipients
17. A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis
18. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
19. Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online
20. A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity
21. Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation
22. Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice
23. Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs
24. Therapeutic Drug Monitoring of Everolimus
25. Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs
26. Lessons From Routine Dose Adjustment of Tacrolimus in Renal Transplant Patients Based on Global Exposure
27. Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin.
28. Large Scale Analysis of Routine Dose Adjustments of Mycophenolate Mofetil Based on Global Exposure in Renal Transplant Patients
29. Development and Evaluation of a Simulation Procedure to Take Into Account Various Assays for the Bayesian Dose Adjustment of Tacrolimus
30. Multisite Analytical Evaluation of the Abbott ARCHITECT Cyclosporine Assay
31. Stability of Ribavirin Concentrations Depending on the Type of Blood Collection Tube and Preanalytical Conditions
32. Pharmacokinetic Modeling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving the Tacrolimus Once-Daily Formulation
33. Rheumatoid Factor Interference in a Tacrolimus Immunoassay
34. Mycophenolic Acid 12-Hour Area Under the Curve in De Novo Liver Transplant Patients Given Mycophenolate Mofetil at Fixed Versus Concentration-Controlled Doses
35. Performance of the New Mycophenolate Assay Based on IMPDH Enzymatic Activity for Pharmacokinetic Investigations and Setup of Bayesian Estimators in Different Populations of Allograft Recipients
36. Feasibility of Ribavirin Therapeutic Drug Monitoring in Hepatitis C
37. Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference
38. Multicenter Evaluation of a New Inosine Monophosphate Dehydrogenase Inhibition Assay for Quantification of Total Mycophenolic Acid in Plasma
39. Proceedings of the 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology
40. Determination of Mycophenolic Acid Plasma Levels in Renal Transplant Recipients Co-administered Sirolimus: Comparison of an Enzyme Multiplied Immunoassay Technique (EMIT) and Liquid Chromatography–Tandem Mass Spectrometry
41. Letter to the Editor
42. Clinical Application of Population Pharmacokinetic Methods Developed for Immunosuppressive Drugs
43. Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods
44. Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5
45. Comparison of Liquid Chromatography-Tandem Mass Spectrometry with a Commercial Enzyme-Multiplied Immunoassay for the Determination of Plasma MPA in Renal Transplant Recipients and Consequences for Therapeutic Drug Monitoring
46. Progress of Liquid Chromatography–Mass Spectrometry in Clinical and Forensic Toxicology
47. Is LC-MS Suitable for a Comprehensive Screening of Drugs and Poisons in Clinical Toxicology?
48. Comparison of Liquid Chromatography-Tandem Mass Spectrometry with a Commercial Enzyme-Multiplied Immunoassay for the Determination of Plasma MPA in Renal Transplant Recipients and Consequences for Therapeutic Drug Monitoring
49. Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients
50. Rheumatoid factor interference in a tacrolimus immunoassay.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.